Top brokers have named Australia and New Zealand Banking GrpLtd (ASX:ANZ) and these ASX shares as buys this week. Here’s why they are bullish on them…
The post Top brokers name 3 ASX shares to buy today appeared first on Motley Fool Australia. –
Many of Australia’s top brokers have been busy adjusting their financial models again, leading to the release of a large number of broker notes this week.
Three broker buy ratings that have caught my eye are summarised below. Here’s why brokers think these ASX shares are in the buy zone:
Australia and New Zealand Banking GrpLtd (ASX: ANZ)
According to a note out of Credit Suisse, its analysts have retained their outperform rating and $26.20 price target on this banking giant’s shares after it announced a $528 million hit to earnings from large notable items. The broker was surprised by the additional remediation, as it thought ANZ was further along with the process. In light of these notable items, the broker has cut its final dividend forecast down to 33 cents per share. Nevertheless, it still appears to see a lot of value in its shares at the current level and retains its outperform rating. I agree that ANZ is a buy. Though, with its results being released tomorrow, it might be best to keep your powder dry until after their release.
Bravura Solutions Ltd (ASX: BVS)
Analysts at Goldman Sachs have retained their buy rating but trimmed the price target on this fintech company’s shares to $4.50 following the announcement of a long term contract win and the release of an updated FY 2021 outlook. Goldman believes that Bravura’s deal pipeline is strong, but fears timing delays could weigh on its earnings in the short term. In light of this, it has trimmed its earnings forecasts slightly. Nevertheless, it remains positive on the future and expects its shift to relatively more SaaS income to result in a re-rating of the stock eventually. I agree with Goldman Sachs and would be a buyer of its shares.
Cochlear Limited (ASX: COH)
A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and $241.00 price target on this hearing solutions company’s shares. The broker has undertaken industry research and surveyed audiologists with a speciality in cochlear implants. It found that demand levels have been improving and Cochlear is gaining market share. This appears to position the company to rebound strongly from the pandemic. I think Macquarie is spot on and Cochlear is a great option.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- 5 things to watch on the ASX 200 on Wednesday
- ANZ (ASX:ANZ) share price on watch after revealing $528 million earnings hit
- Why is the Bravura (ASX:BVS) share price dropping today?
- Is the ANZ (ASX:ANZ) share price a buy today?
- ASX 200 Weekly Wrap: ASX snaps winning streak… just
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Bravura Solutions Ltd and Cochlear Ltd. The Motley Fool Australia has recommended Bravura Solutions Ltd and Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.